The Company has decided to provide Relyvrio through a free drug program for those who wish to stay on therapy. Approved in September 2022, Relyvrio is an oral, fixed-dose coformulation of sodium ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that ...
Credit: Pyros Pharmaceuticals. The prescribing information for Vigpoder carries a Boxed Warning associated with a risk for permanent vision loss. Vigpoder ™ (vigabatrin) for oral solution has ...
Covering news that matters to OU, in Norman or around the world. Robust news organizations like ours generate civic good that informs, improves and inspires communities. For those invested in OU and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results